GlassScriptPhysician profile
Madison Boles
NPI 1467071969
$747.89
in general payments reported to CMS, 2019-2025
13 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $132 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $157.74 | 2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $141.31 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.73 | 2024-2025 | Xifaxan |
| Pfizer INC. | $66.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.34 | 2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $38.68 | 2025 | General - Erectile Dysfunction, Bodyguardian |
| Phathom Pharmaceuticals, INC. | $36.36 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $34.64 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $33.72 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $27.34 | 2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $18.56 | 2025 | |
| Lilly USA, LLC | $17.96 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Boles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.